Cidara Therapeutics (CDTX) Reports Q1 Loss, Lags Revenue Estimates

09:35pm, Wednesday, 11'th May 2022 Zacks Investment Research
Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of -3.85% and 3.93%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
SAN DIEGO, May 11, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patient
Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of -3.85% and 3.93%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Halozyme Therapeutics (HALO) Q1 Earnings and Revenues Miss Estimates

09:25pm, Tuesday, 10'th May 2022 Zacks Investment Research
Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of -2.08% and 7.59%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
SAN DIEGO and CAMBRIDGE, United Kingdom, April 14, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX) and Mundipharma today announced that the companies will present new clinical data a
CD388 is a drug-Fc conjugate (DFC) from Cidara’s Cloudbreak® platform and is designed to transform the standard of care for seasonal influenza prevention

Cidara Therapeutics (CDTX) Reports Q4 Loss, Tops Revenue Estimates

11:55pm, Monday, 07'th Mar 2022 Zacks Investment Research
Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of 21.21% and 84.78%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
SAN DIEGO, March 07, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patie
Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of 21.21% and 84.78%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Mundipharma and Cidara Therapeutics (CDTX) said that the Medicines and Healthcare Products Regulatory Agency ((MHRA)) in the U.K. granted rezafungin Promising Innovative Medicine…

Will Cidara Therapeutics (CDTX) Report Negative Q4 Earnings? What You Should Know

08:02pm, Thursday, 17'th Feb 2022 Zacks Investment Research
Cidara Therapeutics (CDTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The FDA has signed off Cidara Therapeutics Inc'' s (NASDAQ: CDTX ) Investigational New Drug (IND) application for its lead flu drug-Fc conjugate (DFC), CD388 for influenza. CD388 is a highly potent, long-acting antiviral immunotherapy designed to deliver universal prevention and treatment of seasonal and pandemic influenza, added the Company. Cidara Full story available on Benzinga.com
Cidara Therapeutics (CDTX) is trading ~3% higher in the pre-market on Monday after the company announced that the FDA accepted its Investigational New Drug ((IND)) application for the…
The FDA has signed off Cidara Therapeutics Inc's (NASDAQ: CDTX) Investigational New Drug (IND) application for its lead flu drug-Fc conjugate (DFC), CD388 for influenza. CD388 is a highly potent, lo
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE